[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2016-2020 Italy Tumor Marker Testing Market: Supplier Shares by Test, Country Volume and Sales Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive Strategies, Emerging Opportunities

May 2016 | 570 pages | ID: 2836B655621EN
Venture Planning Group

US$ 5,440.00 US$ 6,800.00 -20 %

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Complete report $6,800. DataPack (test volumes, sales forecasts, supplier shares) $4,350.

VPGMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the Italian cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.

RationaleThe cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.Business Opportunities and Strategic Recommendations- Specific new product development opportunities with potentiallysignificant market appeal during the next five years.- Design criteria for new products.- Alternative market penetration strategies. Potential market entry barriers and risks.Cancer Diagnostic Tests Over 200 current and emerging assays including:ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA,Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.Market Segmentation Analysis
  • Sales and market shares of major suppliers, by individual cancer diagnostic test.
  • Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:
    • Hospitals
    • Commercial/Private Laboratories
    • Comprehensive market segmentation analysis, including reviewof the market dynamics, structure, size, growth and major suppliers.
  • Cancer statistics, etiology and recent developments.
Current and Emerging Products
  • Review of over 200 current and emerging cancer diagnostic tests,including:
    • Biochemical Markers
    • Oncogenes
    • Growth Factors
    • Hormones
    • Colony Stimulating Factors
    • Lymphokines
    • Immunohistochemical Stains, and others.
  • Analysis of major immunoassay analyzers used forcancer diagnostic testing, including their operating characteristics,features and selling prices.
Technology Review- Assessment of monoclonal antibodies, immunoassays, DNAprobes, biochips/microarrays, chromosome analysis, IT,artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.- Review of competing/complementing technologies, includingCT, MRI, NMR, PET and photonics spectroscopy.- Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.Competitive AssessmentsStrategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborativearrangements, and new products in R D.

Contains 570 pages and 83 tables
1. INTRODUCTION

2. WORLDWIDE MARKET OVERVIEW

  1. MARKET OVERVIEW
  2. WORLDWIDE MARKET STRUCTURE
  3. WORLDWIDE MARKET SIZE AND GROWTH

3. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products

4. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

5. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies

6. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

7. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology
  1. BREAST CANCER
  2. LUNG CANCER
  3. COLON AND RECTUM CANCER
  4. PROSTATE CANCER
  5. STOMACH CANCER
  6. LEUKEMIA
  7. LYMPHOMA
  8. ORAL CANCER
  9. SKIN CANCER
  10. UTERINE CANCER
  11. OVARIAN CANCER
  12. BLADDER CANCER
B. Major Current And Emerging Cancer Diagnostic Tests
  1. INTRODUCTION
  2. TUMOR MARKER CLASSIFICATION
  3. ACTH
  4. ALPHA FETOPROTEIN (AFP)
  5. BETA 2 MICROGLOBULIN
  6. CA 15 3/27.29
  7. CA 199
  8. CA 125
  9. CALCITONIN
  10. CARCINOEMBRIONIC ANTIGEN (CEA)
  11. ESTROGEN AND PROGESTERONE RECEPTORS
  12. FERRITIN
  13. GASTRIN
  14. HUMAN CHORIONIC GONADOTROPIN (HCG)
  15. INSULIN
  16. NSE
  17. OCCULT BLOOD
  18. PAP SMEAR/HPV
  19. PROSTATIC ACID PHOSPHATASE (PAP)
  20. PROSTATE    SPECIFIC ANTIGEN (PSA)
  21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
  22. T AND B LYMPHOCYTES
  23. TDT
  24. THYROGLOBULIN
  25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
  26. BIOCHEMICAL TUMOR MARKERS
  27. ONCOGENES
  Abl/abl bcr
  AIB1
  BCL2
  BRCA1
  CD44
  C-fos
  C-myb
  C-myc
  CYP    17
  ErbB
  HPC1
  Nmyc
  P40
  P51
  P53
  PIK3CA
  PTI1
  Ras
  Reg
  Sis
  Src
  28. POLYPEPTIDE GROWTH FACTORS
  Basic Fibroblast Growth Factor
  Beta    TGF
  Cachectin (TNT)
  Calmodulin
  ECFR
  Nerve Growth Factor (NGF)
  Epidermal Growth Factor (EGF)
  Ornithine Decarboxylase
  Transferrin
  Transforming Growth Factor    Alpha
  29. ECTOPIC HORMONES
  30. COLONY STIMULATING FACTORS
  31. LYMPHOKINES
  Alpha    Interferon
  B Cell Growth Factors
  B Cell Growth Factor (BCGF)
  Gamma    Interferon
  Interleukin    1 (IL1)
  Macrophage Activating Factor
  32. IMMUNOHISTOCHEMICAL STAINS
  33. EMERGING TUMOR MARKERS
  NAcetylglucosamine
  Actin
  Alpha    Actin
  Antineuronal Antibodies
  7B2
  B72.3
  Bax
  BCD    F9
  BLCA 4
  Blood Group Antigens A, B, H
  CA
  CA 72    4/TAG    72
  CA
  CA 242
  CA 549
  CAM
  CAR    3
  Cathepsin    D
  Chromogranin A and B
  Cluster 1 Antigen
  Cluster    5/5A Antigen
  CTA
  CU18
  DR    70
  DU    AN2
  Endometrial Bleeding Associated Factor
  Endostatin
  Epithelial Membrane Antigen
  Feulgen Hydrolysis
  Fibronectin
  FSH
  (1    >3)    Lfucosyltransferase
  Gastrin    Releasing Peptide (GRP)
  GDCFP    15
  Glucagon
  Glycoamines
  H23
  Her    2
  Human Carcinoma Antigen
  HPA
  HSP27
  Intermediate Filaments
  Cytokeratins/CK18/Cyfra 21    1
  Desmin
  Gliofibrillary Acid Protein
  Neurofilaments
  Vimentin
  KA
  Kinases
  KP16D3
  LAI
  Leukocyte Common Antigen
  Lewis Antigens
  Lysophosphatidic Acid (LPA)
  Ma 695/Ma
  MABDF3
  MAG
  ME1
  Minactivin
  MN/CA9
  MSA
  Mucin Cancer Antigen (MCA)
  Multiple Tumor Suppressor
  Myosin
  NEA 130
  NMP22
  OA 519
  Opioid Peptides
  P    glycoprotein
  Pancreatic Oncofetal Antigen (POA)
  Placental Lactogen
  PR92
  Proliferative Index, Ki 67
  Px
  RB Inactivation/Deletion
  Ret
  SCCL
  Selectin
  Sialic Acid
  Sialyl SSEA 1/SLX
  SN10
  Somatostatin
  TA 90
  TABA
  Tachykinin
  TAG
  TPS
  Troponin
  Tubulin
  VCAM
  VEGF
  Villen
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
  1. MONOCLONAL AND POLYCLONAL ANTIBODIES
  2. IMMUNOASSAYS
  3. MOLECULAR DIAGNOSTICS
  4. CHROMOSOME ANALYSIS
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. ARTIFICIAL INTELLIGENCE
  6. FLOW CYTOMETRY
  7. TW DIMENSIONAL GEL ELECTROPHORESIS (2    DGE)
  8. BIOSENSORS
  9. COMPETING/COMPLEMENTING TECHNOLOGIES
E. Personal Testing

8. ITALY CANCER DIAGNOSTICS MARKET

A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test

9. COMPETITIVE PROFILES

  Abbott
  AdnaGen/Alere
  Agilent Technologies
  Applied Gene Technologies
  Arca Biopharma
  Beckman Coulter/Danaher
  Becton Dickinson
  Biomedical Diagnostics
  bioMerieux
  Bio-Rad
  CellSearch
  Cepheid
  Correlogic Systems/Vermillion
  Decode Genetics
  Diadexus
  Diagnocure
  Diasorin
  Eiken Chemical
  Elitech Group
  Enterix
  Enzo Biochem
  Epigenomics
  Exact Sciences
  Fujirebio
  Guided Therapeutics
  Hologic/Genrobe
  Kreatech/Leica
  Kyowa Medex
  Mackay Life Sciences
  Myriad Genetics
  OncoLab
  Ortho    Clinical Diagnostics
  Panacea Pharmaceuticals
  Polartechnics
  Polymedco
  PreMD
  Qiagen
  Quest Diagnostics
  Radient Pharmaceuticals
  Roche
  Scienion
  Sequenom
  Siemens Healthcare
  Takara Bio
  Targeted Diagnostics & Therapeutics
  Tosoh
  Thermo
  Veridex
  Wako Pure Chemicals
  Wallac/PE
  Zila

10. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS

LIST OF TABLES

Tumor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta    2 Microglobulin Tests
Major Companies Developing or Marketing CA 15 3/27.29 Tests
Major Companies Developing or Marketing CA 199 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer Diagnosis
Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis
Executive Summary Table: Italy, Total Tumor Marker Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, Estimated Cancer Death Rates Per 100, 000 Population
Italy, Laboratories Performing Tumor Marker Tests by Market Segment
Italy, Hospital Laboratories Performing Tumor Marker Tests by Bed Size
Italy, Commercial/Private Laboratories Performing Tumor Markers by Annual Test Volume
Italy, Total Tumor Marker Test Volume Forecast by Market Segment
Italy, All Market Segments Major Cancer Diagnostic Test Volume Forecast
Italy, Hospital Laboratories Major Tumor Marker Test Volume Forecast
Italy, Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
Italy, Total Tumor Marker Test Market Forecast by Market Segment
Italy, All Market Segments Major Tumor Marker Sales Forecast by Test
Italy, Hospital Laboratories Major Tumor Marker Forecast by Test
Italy, Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
Italy, ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, AFP Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, Beta    2 Microglobulin Test Volume And Diagnostics Sales Forecast by Market Segment
Italy, CA 15 3/27.29 Test Volumeand Diagnostics Sales Forecast by Market Segment
Italy, CA 199 Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, CA 125 Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, CEA Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, Chromogranin Test Volume And Diagnostics Sales Forecast by Market Segment
Italy, Colon Specific Antigen Test Volume And Diagnostics Sales Forecast by Market Segment
Italy, Cytokeratins Test Volumeand Diagnostics Sales Forecast by Market Segment
Italy, Estrogen Receptor Test Volumeand Diagnostics Sales Forecast by Market Segment
Italy, Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, HCG Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, Lymphocyte Subtyping Test Volume And Diagnostics Sales Forecast by Market Segment
Italy, NSE Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast By Market Segment
Italy, PAP Smear Test Volumeand Diagnostics Sales Forecast by Market Segment
Italy, Parathyroid Hormone Test Volumeand Diagnostics Sales Forecast by Market Segment
Italy, Progesterone Receptor Test Volumeand Diagnostics Sales Forecast by Market Segment
Italy, PAP Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, PSA Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, S    100 Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, Serotonin Test Volumeand Diagnostics Sales Forecast by Market Segment
Italy, Sialic Acid Test Volumeand Diagnostics Sales Forecast by Market Segment
Italy, Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast By Market Segment
Italy, TDT Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, Thymidine Kinase Test Volumeand Diagnostics Sales Forecast by Market Segment
Italy, Thyroglobulin Test Volumeand Diagnostics Sales Forecast by Market Segment
Italy, TPA Test Volume and Diagnostics Sales Forecast by Market Segment
Italy, Total Tumor Markers Sales by Major Suppliers
Italy, AFP Testing Market Diagnostics Sales by Major Supplier
Italy, CEA Testing Market Diagnostics Sales by Major Supplier
Italy, PSA Testing Market Diagnostics Sales by Major Supplier


More Publications